Kura Oncology, Inc.
Financials
Valuation Metrics
Kura Oncology, Inc.'s Market Cap is $1.04B. At end of 2025 it was $915M. Ranked #2456 of 3,121 in US market (top 79%), #1005 of 1,463 on NASDAQ (top 69%), #186 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.04B | US#2,456/3,121 Sec#186/266 |
| Revenue | $77M | US#2,739/3,121 Sec#136/266 |
| Net Income | $-297M | US—/3,121 Sec—/266 |
| Total Assets | $588M | US#2,705/3,121 Sec#143/266 |
| Net Assets | $48M | US#2,868/3,121 Sec#225/266 |
| Employees | 260 | US#2,450/3,121 Sec#119/266 |
| Value | ||
| P/B | 21.50x | US#2,807/3,121 Sec#220/266 |
| P/S | 13.48x | US#2,764/3,121 Sec#123/266 |
| FCF Yield | -11.28% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -50.49% | US#2,991/3,121 Sec#214/266 |
| Op. Margin | -411.90% | US#2,798/3,121 Sec#150/266 |
| Revenue Growth | -7.27% | US#2,554/3,121 Sec#143/266 |
| Financial Health | ||
| Debt Ratio | 1113.67% | US#2,764/3,121 Sec#231/266 |
| Total Debt | $24M | US#2,729/3,121 Sec#183/266 |
| FCF | $-117M | US#2,661/3,121 Sec#157/266 |
| Cash | $70M | US#2,424/3,121 Sec#204/266 |
| Current Ratio | 4.73x | US#508/3,121 Sec#152/266 |
| Performance | ||
| 1Y Return | 38.98% | US#636/3,121 Sec#116/266 |
| 1M Return | -6.38% | US#1,701/3,121 Sec#140/266 |
| From 52W High | -15.61% | US#1,185/3,121 Sec#80/266 |
| 1Y MDD | -39.04% | US#1,966/3,121 Sec#135/266 |
| Trading | ||
| Volume | 2,303,264 shares | US#899/3,121 Sec#93/266 |
| Trading Value | $27M | US#1,840/3,121 Sec#144/266 |
| Per Share | ||
| EPS | $-3.34 | US—/3,121 Sec—/266 |
| BPS | $0.55 | US#2,752/3,121 Sec#219/266 |
Company Info
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.